PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Description

This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.

Conditions

Hereditary Angioedema

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.

A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Condition
Hereditary Angioedema
Intervention / Treatment

-

Contacts and Locations

Scottsdale

KalVista Investigative Site, Scottsdale, Arizona, United States, 85251

Little Rock

KalVista Investigative Site, Little Rock, Arkansas, United States, 72205

San Diego

KalVista Investigative Site, San Diego, California, United States, 92122

San Diego

KalVista Investigative Site, San Diego, California, United States, 92123

Santa Monica

KalVista Investigative Site, Santa Monica, California, United States, 90404

Centennial

KalVista Investigative Site, Centennial, Colorado, United States, 80112

Colorado Springs

KalVista Investigative Site, Colorado Springs, Colorado, United States, 80907

Evansville

KalVista Investigative Site, Evansville, Indiana, United States, 47715

Overland Park

KalVista Investigative Site, Overland Park, Kansas, United States, 66211

Louisville

KalVista Investigative Site, Louisville, Kentucky, United States, 40215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female adolescent patient 12 to 17 years of age at the time of enrollment and during sample collection in this PK subtrial.
  • * Patient is currently participating in KVD900-302.
  • * Patient must provide signed informed consent or assent (when applicable), and a legally authorized representative (LAR) must also provide signed informed consent when applicable.
  • * Patient and LAR are willing and able to provide samples per the requirements of the protocol, including willingness to complete forms and the electronic Diary, obtain and return samples in a timely manner, and obtain samples while within the required age limit.
  • * Patient has a history of any bleeding disorder or currently taking any anti-coagulant or anti-platelet agent.

Ages Eligible for Study

12 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

KalVista Pharmaceuticals, Ltd.,

Study Director, STUDY_DIRECTOR, KalVista Pharmaceuticals, Ltd.

Study Record Dates

2026-06-30